Should I Keep Taking Myo-Inositol While Pregnant?

Myo-inositol has a strong safety profile during pregnancy, and for many women, especially those at higher risk of gestational diabetes, continuing it makes sense. The supplement carries FDA “generally recognized as safe” (GRAS) status and has been used in prenatal clinical trials without serious adverse effects. But “safe to keep taking” and “beneficial to keep taking” are different questions, and a large 2025 trial in women with polycystic ovary syndrome threw cold water on the assumption that myo-inositol helps every pregnant person equally. Whether you should continue depends on why you started it and what your individual risk factors look like.

The Safety Picture Is Reassuring

Across clinical trials where daily doses have ranged from about 4 grams up to 60 grams and treatment lasted anywhere from one to twelve months, the only adverse events tied to myo-inositol were mild gut symptoms: nausea, gas, and loose stools. Those complaints surfaced almost exclusively at doses above 12 grams a day, which is well above what pregnancy supplements typically contain. Importantly, the severity of those symptoms did not worsen as doses climbed from 12 grams toward 30 grams. Myo-inositol has also been tested in preterm infants as young as 29 weeks’ gestational age at doses up to 80 mg per kilogram per day for more than 10 weeks, with no increase in adverse events compared to controls.¹

Regarding fetal safety specifically, the transplacental passage of myo-inositol does not appear to be clinically significant. In mouse studies, exposing preimplantation embryos to myo-inositol produced no early toxic effects and actually increased the rate of live births compared with untreated embryos. The FDA’s GRAS designation extends to use in infants, which is a meaningful stamp of confidence given how cautious regulators tend to be about that age group.¹

Where the Evidence Is Strongest: Preventing Gestational Diabetes in High-Risk Women

The most consistent benefit of myo-inositol supplementation during pregnancy shows up in women who are already at elevated risk for gestational diabetes, meaning those who are overweight or obese, have PCOS, or have a family history of type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials found that inositol supplementation roughly halved the incidence of gestational diabetes compared with placebo. When the analysis narrowed to trials using myo-inositol specifically, the risk reduction was even more dramatic, with about a 70 percent lower chance of developing the condition.²

A separate meta-analysis focusing on overweight and obese pregnant women found a similarly striking result, with the myo-inositol group showing roughly a third the odds of developing gestational diabetes compared to controls.³ The evidence is consistent enough that multiple review papers treat this as an established finding for at-risk populations.⁴

If you started myo-inositol because you fall into one of these risk categories, the existing evidence supports continuing through pregnancy. That said, a caveat worth holding in your mind is that many of these trials were conducted in Italy with specific populations, and the total number of participants across all trials is still modest by the standards of, say, prenatal vitamin research.

The PCOS Trial That Complicated the Picture

In 2025, a well-designed randomized trial published in JAMA tested myo-inositol against placebo in 464 pregnant women with PCOS, a group that should theoretically benefit from the supplement. The results were a letdown: a composite of gestational diabetes, preeclampsia, and preterm birth occurred in 25 percent of the myo-inositol group versus about 27 percent of the placebo group, a difference so small it was statistically meaningless. The authors concluded that myo-inositol supplementation during pregnancy did not reduce the incidence of these complications in women with PCOS.⁵

This trial matters because it was larger and more rigorous than most of the earlier studies. An accompanying editorial acknowledged that while myo-inositol has been shown to improve insulin sensitivity and conception rates in PCOS, evidence for improving actual pregnancy outcomes in this population had been lacking, and the trial confirmed that gap.⁶

How do you square a trial showing no benefit in PCOS with meta-analyses showing dramatic reductions in gestational diabetes? One explanation is that the earlier positive trials specifically enrolled women based on metabolic risk factors like obesity or impaired fasting glucose, while the JAMA trial enrolled all women with PCOS regardless of their metabolic profile. PCOS is a heterogeneous condition. Not every woman with it has significant insulin resistance, and women without metabolic dysfunction may have less room for myo-inositol to help. The trial also measured a composite outcome that lumped together gestational diabetes, preeclampsia, and preterm birth. Even if myo-inositol had a modest effect on one of those, it could have been diluted when bundled with the others.

One practical finding did emerge: the myo-inositol group had a lower rate of planned cesarean delivery. That’s an interesting signal, but it wasn’t the primary outcome and should be treated cautiously.

If You Already Have Gestational Diabetes

Some women start taking myo-inositol not to prevent gestational diabetes but to help manage it after diagnosis. There is evidence that it can meaningfully improve blood sugar control. In a study of women who had already been diagnosed with gestational diabetes, those treated with myo-inositol had significantly lower fasting blood sugar and lower post-dinner glucose readings compared to those who did not receive the supplement. Perhaps more importantly, the myo-inositol group needed less insulin in both the second and third trimesters.⁷

Needing less insulin is a real quality-of-life benefit. Insulin injections are burdensome, they carry their own risks of hypoglycemia, and anything that reduces the required dose while keeping blood sugar in range is worth considering. If your healthcare provider has you on myo-inositol as part of a gestational diabetes management plan, the data supports continuing. This is different from the prevention question, and the evidence here is more consistently positive.

Typical Doses and What to Expect

Most pregnancy trials have used 2 grams of myo-inositol twice daily, for a total of 4 grams per day.⁸ This is the dose with the most safety data behind it and the one that the gestational diabetes prevention trials have largely converged on. Some products combine myo-inositol with folic acid or D-chiro-inositol, but the 4 grams per day myo-inositol figure is the anchor.

At this dose, side effects are uncommon. When they do show up, they are the mild gastrointestinal symptoms mentioned earlier. If you experience bloating or loose stools, splitting the dose across meals sometimes helps. The safety reviews consistently note that symptoms become noticeable only at doses above 12 grams per day, which is triple the standard supplementation amount.¹

Why Pregnancy Changes Your Inositol Levels

Your body handles myo-inositol differently when you are pregnant. Urinary excretion of myo-inositol increases roughly threefold in early pregnancy and more than fivefold later in gestation compared to postpartum levels. Women who go on to develop gestational diabetes show even greater excretion of myo-inositol during the first trimester, suggesting their bodies are losing more of it through the kidneys at the very stage when metabolic demands are ramping up.⁹

This finding gives a biological rationale for supplementation. If pregnancy is essentially draining your myo-inositol stores faster than you can replenish them, and if that depletion is linked to insulin resistance, then replacing what is being lost makes physiological sense. It also helps explain why the supplement might be more effective in women who already have metabolic stress: they are losing more myo-inositol to begin with, so they stand to gain more from topping it back up.

Myo-Inositol Versus D-Chiro-Inositol

Myo-inositol is not the only inositol isomer you will see on supplement labels. D-chiro-inositol is another form, and some products combine the two. A trial in pregnant women with elevated fasting glucose tested a combination of 1.75 grams per day of myo-inositol plus 250 milligrams per day of D-chiro-inositol against folic acid alone. The combination group had a substantially lower rate of gestational diabetes and a lower rate of macrosomia, which is when a newborn weighs more than about 9 pounds.¹⁰

The ratio of myo-inositol to D-chiro-inositol matters. In the body, these two isomers exist at roughly a 40:1 ratio, and most researchers studying insulin signaling recommend maintaining something close to that physiological balance. Too much D-chiro-inositol on its own can actually impair egg quality in the PCOS context, which is why most reproductive endocrinologists favor myo-inositol as the primary supplement and use D-chiro-inositol only in smaller complementary amounts. If you are choosing a combined product, look for one that keeps the D-chiro portion relatively low compared to the myo-inositol.

Neural Tube Defects and an Intriguing Early Signal

Most people associate neural tube defect prevention with folic acid, but there is a small body of research suggesting myo-inositol might add an extra layer of protection. A pilot randomized controlled trial enrolled women who had previously had a pregnancy affected by a neural tube defect. Among the 14 randomized pregnancies in the inositol-plus-folic-acid group, there were no recurrences. In the 19 pregnancies in the placebo-plus-folic-acid group, there was one recurrence. Among 22 additional non-randomized pregnancies that the researchers tracked, two more neural tube defects occurred, both in women who had taken only folic acid.¹¹

These numbers are too small to be conclusive. But they are interesting because some neural tube defects appear to be “folate-resistant,” meaning they happen even when the mother takes adequate folic acid. The possibility that myo-inositol works through a different pathway to reduce that residual risk is biologically plausible and is being studied further. This should not be a reason to start myo-inositol if you were not already considering it, but it is worth knowing about if you are already taking it and wondering whether there is any point continuing.

Preterm Birth

Several of the gestational diabetes prevention trials reported preterm birth rates as a secondary outcome, and a narrative review proposed a biological mechanism by which myo-inositol might reduce the risk: higher inositol levels in the uterus and placenta could dampen inflammatory signaling that contributes to early labor onset.¹² The idea is biologically interesting, but the clinical evidence so far does not support it convincingly. The 2025 JAMA trial in women with PCOS found no reduction in preterm birth with myo-inositol.⁵ Until a trial is designed specifically to test preterm birth as a primary endpoint, this remains a hypothesis rather than a reason to take the supplement.

What We Do Not Know Yet

The biggest gap in the myo-inositol-in-pregnancy literature is what happens to the children long term. A Cochrane systematic review examining myo-inositol supplementation for treating gestational diabetes found that no studies had reported long-term outcomes for the mother, the infant as a child, or the infant as an adult.¹³ This is not alarming per se. Given the supplement’s GRAS status, its presence in common foods, and its role as a naturally occurring molecule in human cells, a hidden harm would be surprising. But the honest answer is that nobody has followed these children for years to confirm that nothing subtle is going on.

There is also limited data on how myo-inositol interacts with metformin, which some women take during pregnancy for blood sugar management or PCOS. A narrative review suggested that both agents target insulin resistance and could theoretically complement each other, but acknowledged that randomized trials confirming this in pregnant women are lacking.¹⁴ If you are on metformin and myo-inositol simultaneously, your provider should be aware, even though no specific interaction has been flagged.

How Myo-Inositol Affects Placental Function

Research into the placenta is starting to give a more detailed picture of what myo-inositol does at the tissue level during pregnancy. A study examining how the placenta handles DHA, a key omega-3 fatty acid critical for fetal brain development, found that myo-inositol appeared to moderate the relationship between maternal body weight, blood sugar levels, and placental fat processing. In placentas supporting babies with lower birthweight, myo-inositol increased DHA lipid handling, while in placentas supporting babies with higher birthweight, it had the opposite effect. The net result looked like a normalizing influence, nudging placental function toward a middle ground around the 50th to 60th birthweight percentile.¹⁵

This is early-stage laboratory work, not a clinical trial you can draw direct guidance from. But it suggests that myo-inositol is not simply a blunt tool that pushes one metabolic dial in one direction. Instead, it seems to have a regulating effect that adjusts based on what the placenta already needs. If confirmed in clinical settings, this would help explain why the supplement shows clearer benefits in metabolically stressed pregnancies while producing no obvious signal in healthy ones.

Inositol in Food and What Counts as Supplementation

Myo-inositol is not an exotic compound. Your body makes it, and you get it from food. Citrus fruits, beans, nuts, whole grains, and cantaloupe are all reasonable sources. A typical Western diet provides somewhere around 1 gram per day of myo-inositol, though estimates vary. That dietary intake is well below the 4 grams per day used in clinical trials, which is why food sources alone are unlikely to reproduce the supplementation effects seen in research.

If you eat a diet rich in whole foods, you are getting some baseline myo-inositol. But if you are relying on dietary intake alone to match what the trials tested, you would need to eat unrealistic quantities. The practical divide is simple: dietary myo-inositol contributes to your overall status, but the doses associated with gestational diabetes prevention require a supplement.

One more thing to know: because pregnancy increases your kidneys’ clearance of myo-inositol, even a good diet may leave you with less circulating myo-inositol than you had before pregnancy. This is the biological backdrop against which the supplementation question sits, and it applies regardless of which specific risk category you fall into.